WallStSmart

Ventas Inc (VTR)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ventas Inc generates 2147% more annual revenue ($5.82B vs $258.90M). VTR leads profitability with a 4.3% profit margin vs -15.5%. VTR earns a higher WallStSmart Score of 55/100 (C).

VTR

Buy

55

out of 100

Grade: C

Growth: 7.3Profit: 5.0Value: 4.7Quality: 3.8
Piotroski: 4/9Altman Z: 0.39

ZEPP

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VTRSignificantly Overvalued (-591.0%)

Margin of Safety

-591.0%

Fair Value

$12.40

Current Price

$82.70

$70.30 premium

UndervaluedFair: $12.40Overvalued

Intrinsic value data unavailable for ZEPP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VTR2 strengths · Avg: 8.0/10
Operating MarginProfitability
20.3%8/10

Strong operational efficiency at 20.3%

Revenue GrowthGrowth
21.4%8/10

Revenue surging 21.4% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VTR4 concerns · Avg: 3.0/10
PEG RatioValuation
1.744/10

Expensive relative to growth rate

Return on EquityProfitability
2.2%3/10

ROE of 2.2% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

P/E RatioValuation
153.2x2/10

Premium valuation, high expectations priced in

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$216.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : VTR

The strongest argument for VTR centers on Operating Margin, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VTR

The primary concerns for VTR are PEG Ratio, Return on Equity, Profit Margin. A P/E of 153.2x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VTR profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.59 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor REIT - HEALTHCARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTR scores higher overall (55/100 vs 43/100) and 21.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ventas Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?